Granulocyte-macrophage colony-stimulating factor - Cangene

Drug Profile

Granulocyte-macrophage colony-stimulating factor - Cangene

Alternative Names: GM-CSF Cangene; Granulocyte-macrophage colony-stimulating factor; Leucotropin; rhGM-CSF

Latest Information Update: 28 Feb 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cangene Corporation
  • Developer Apotex; Cangene Corporation; Emergent BioSolutions
  • Class Adjuvants; Glycoproteins; Granulocyte-macrophage colony-stimulating factors
  • Mechanism of Action Granulocyte macrophage colony stimulating factor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer; Neutropenia

Most Recent Events

  • 21 Feb 2014 Cangene Corporation has been acquired and merged into Emergent BioSolutions
  • 19 Jul 2013 Biomarkers information updated
  • 14 Mar 2007 Leucotropin® is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top